Summary
The goal we seek in CoaguPOC project is to develop a “ready to the market” smart point-of-care device for self-patient management of the Oral Anticoagulant Therapy (OAT). OAT is a long-term or even chronic therapy necessary to inhibit the formation of potentially lethal blood clots in patients with high risk of thrombosis; e.g. strokes, the 2nd single largest cause of death in the world. Approximately 2% of the population are prescribed long-term oral anticoagulants, meaning that more than 10-12 million people are treated in Western Europe.
OAT therapy needs regular tests to confirm correct dosage levels because the drugs have a narrow therapeutic window and small changes in systemic changes can give rise to adverse toxic effects. Tests are usually made once a month in a nursing service at the hospital or care center. The constant increase on the number of anti-coagulant patients (around 10% annually) is highly intensifying pressure and cost on the healthcare resources required to monitor, prevent and manage adverse events.
The use of point-of-care coagulometers at home for self-monitoring may avoid unnecessary visits to hospitals or clinics while permitting more frequent monitoring and timely adjustment of anticoagulant dosing to avoid adverse events. The OAT self-management leads to important reductions on adverse events, as thrombosis (reduction by 50%), major hemorrhages (12%), death (18%) and thrombotic events (67%) as compared to ‘usual care‘. It also has a substantial impact on the quality of life of patients and their families, and important cost savings on the healthcare system. For instance, in UK a mere increase of 5% improved in average therapeutic range, led to a reduction of 550 strokes per year and associated cost saving of around €12,000 per patient.
CoaguPOC aims bringing to the market the first low-cost and smart point of care device for OAT patients to self-monitor and self-manage their chronic condition. We aim to bring the lab to your pocket
OAT therapy needs regular tests to confirm correct dosage levels because the drugs have a narrow therapeutic window and small changes in systemic changes can give rise to adverse toxic effects. Tests are usually made once a month in a nursing service at the hospital or care center. The constant increase on the number of anti-coagulant patients (around 10% annually) is highly intensifying pressure and cost on the healthcare resources required to monitor, prevent and manage adverse events.
The use of point-of-care coagulometers at home for self-monitoring may avoid unnecessary visits to hospitals or clinics while permitting more frequent monitoring and timely adjustment of anticoagulant dosing to avoid adverse events. The OAT self-management leads to important reductions on adverse events, as thrombosis (reduction by 50%), major hemorrhages (12%), death (18%) and thrombotic events (67%) as compared to ‘usual care‘. It also has a substantial impact on the quality of life of patients and their families, and important cost savings on the healthcare system. For instance, in UK a mere increase of 5% improved in average therapeutic range, led to a reduction of 550 strokes per year and associated cost saving of around €12,000 per patient.
CoaguPOC aims bringing to the market the first low-cost and smart point of care device for OAT patients to self-monitor and self-manage their chronic condition. We aim to bring the lab to your pocket
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/775471 |
| Start date: | 01-05-2017 |
| End date: | 31-08-2017 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
The goal we seek in CoaguPOC project is to develop a “ready to the market” smart point-of-care device for self-patient management of the Oral Anticoagulant Therapy (OAT). OAT is a long-term or even chronic therapy necessary to inhibit the formation of potentially lethal blood clots in patients with high risk of thrombosis; e.g. strokes, the 2nd single largest cause of death in the world. Approximately 2% of the population are prescribed long-term oral anticoagulants, meaning that more than 10-12 million people are treated in Western Europe.OAT therapy needs regular tests to confirm correct dosage levels because the drugs have a narrow therapeutic window and small changes in systemic changes can give rise to adverse toxic effects. Tests are usually made once a month in a nursing service at the hospital or care center. The constant increase on the number of anti-coagulant patients (around 10% annually) is highly intensifying pressure and cost on the healthcare resources required to monitor, prevent and manage adverse events.
The use of point-of-care coagulometers at home for self-monitoring may avoid unnecessary visits to hospitals or clinics while permitting more frequent monitoring and timely adjustment of anticoagulant dosing to avoid adverse events. The OAT self-management leads to important reductions on adverse events, as thrombosis (reduction by 50%), major hemorrhages (12%), death (18%) and thrombotic events (67%) as compared to ‘usual care‘. It also has a substantial impact on the quality of life of patients and their families, and important cost savings on the healthcare system. For instance, in UK a mere increase of 5% improved in average therapeutic range, led to a reduction of 550 strokes per year and associated cost saving of around €12,000 per patient.
CoaguPOC aims bringing to the market the first low-cost and smart point of care device for OAT patients to self-monitor and self-manage their chronic condition. We aim to bring the lab to your pocket
Status
CLOSEDCall topic
SMEInst-06-2016-2017Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
H2020-EU.2.1.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
